<DOC>
	<DOCNO>NCT01377935</DOCNO>
	<brief_summary>The purpose study compare incidence hospitalization acute kidney injury among patient type 2 diabetes new initiator Saxagliptin new initiator oral antidiabetic drug class Dipeptidyl peptidase IV ( DPP4 ) inhibitor .</brief_summary>
	<brief_title>Risk Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed Oral Antidiabetic Treatments</brief_title>
	<detailed_description>Prospectively design retrospective database study . This study conduct use administrative claim data electronic medical record collect part routine clinical practice . This prospectively-designed database cohort study compare hospitalization acute kidney injury among new initiator Saxagliptin compare new initiator OADs class DPP4 inhibitor . The study time frame 2009 2014 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>18 year age old Newly prescribe Saxagliptin OAD class DPP4 inhibitor Enrolled respective database least 180 day prior first prescription new OAD Patients identify diagnostic code acute kidney injury within 180day baseline period Patients DPP4 inhibitor exposure baseline period Patients currently use Exenatide Insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>